FDA OKs J&J unit's Remicade to treat children's ulcerative colitis

09/25/2011 | Family Practice News · Bloomberg

The FDA approved Remicade, or infliximab, for treating moderate to severe ulcerative colitis in patients ages 6 to 17 who do not respond adequately to conventional therapy. The tumor necrosis factor blocker includes a boxed warning about a risk of cancer and infection. Remicade, made by Johnson & Johnson unit Janssen Biotech, also treats Crohn's disease in children and adults as well as other inflammatory conditions in adults.

View Full Article in:

Family Practice News · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX